Parnax Lab Ltd. – Company Report
1. Company Overview
Parnax Lab Ltd., incorporated in 1982 and headquartered in Mumbai, Maharashtra, is a prominent Indian pharmaceutical manufacturer specializing in the production and export of pharmaceutical formulations. As part of the Naxpar Group, the company is recognized for its expertise in manufacturing a broad array of pharmaceutical, cosmetic, herbal/ayurvedic, and nutraceutical products. Parnax operates globally, catering to both domestic and international market demands, and has built a reputable presence based on quality, compliance, and innovation.
The company is WHO-approved and EHS-compliant, with a focus on contract manufacturing and trading of medicinal products. Its board is helmed by experienced professionals including Managing Director Mihir Prakash Shah, and a leadership team that blends technical and business acumen. Parnax Lab Ltd. is listed on the Bombay Stock Exchange (BSE: 506128) and maintains a steady financial track record with consistent profits and prudent capital management.
- Incorporated: 1982
- Headquarters: Mumbai, Maharashtra, India
- Certifications: WHO-approved, EHS-compliant
- Core Focus: Manufacturing and export of pharmaceutical formulations, nutraceuticals, cosmetics, herbal products
- Leadership: Mihir Prakash Shah (MD & CEO), Binoy Baiju Shah (CFO & Director)
- Market Capitalization (July 2025): Approx. ₹119–136 crore
2. Products and Services
Parnax Lab Ltd. delivers an extensive range of pharmaceutical and allied products, catering to diverse market requirements:
Pharmaceutical Formulations:
- Liquids, oral suspensions, capsules, tablets, ointments, gels, creams, ear drops, and dry syrup preparations
- Products manufactured under strict cGMP and international quality standards for both domestic and export markets
Other Product Segments:
- Diagnostics, medications, and innovative biopharmaceutical solutions
- Healthcare supplements and nutraceuticals
- Herbal and ayurvedic products
- Cosmetics and personal care items
- Food products and alcohol-based formulations
Custom Manufacturing and Trading:
- Specializes in contract manufacturing of liquid orals, capsules, and other dosage forms for partners in India and overseas
- Offers regulatory and technical support for exports and compliance
Highlighted Brands and Products:
- T Dol 200 Tablet, Tramac 50 Capsule, Nerodex Cough Syrup, Gentian Violet Paint, Haemgrow Liquid, and various proprietary blends
3. Recent News and Financial Performance
Recent News and Developments:
- Q4 FY2025 net profit rose 30% to ₹2.92 crore, with sales increasing to ₹49.04 crore.
- For FY2025, net profit reached ₹11.52 crore, up 19.88% YoY, despite marginally lower annual sales of ₹187.74 crore.
- Operating Profit Margin improved to 14%, reflecting increased operational efficiency.
4. Financial Performance (FY2025)
| Metric | FY2025 Value |
|---|---|
| Total Revenue | ₹187.74 crore |
| Net Profit | ₹11.52 crore |
| Operating Profit Margin | 14% |
| Net Profit Margin | 6.1% |
| EPS (Basic) | ₹10.03 |
| ROE | 14.9% |